Facebook Twitter LinkedIn Google Plus RSS

Cambrex to acquire Halo in $425M deal

By ,
Cambrex announced a definitive agreement today of a deal to acquire Halo which is expected to close this quarter.
Cambrex announced a definitive agreement today of a deal to acquire Halo which is expected to close this quarter. - ()

East Rutherford-based Cambrex Corp. will acquire Halo Pharma of Whippany for $425 million.

Cambrex announced a definitive agreement Monday of a deal that’s expected to close this quarter. The acquisition will be funded with a combination of capital on hand and borrowings against Cambrex’s $500 million senior credit facility.

Cambrex (NYSE: CBM) is a publicly traded manufacturer of pharmaceutical products. Halo provides drug product development and commercial manufacturing services, specializing in oral solids, liquids, creams, sterile and non-sterile ointments. Halo’s core competencies include developing and manufacturing highly complex and difficult to produce formulation. Cambrex officials said the acquisition of Halo will allow it to enter new market segments.

“Halo’s expertise in oral solids, liquids, creams and ointments fits well with our [current] business and brings a substantial new customer base and pipeline of small molecule products,” Cambrex CEO Steve Klosk said. “We believe the combination of Cambrex and Halo will attract new customers to the combined company and allow us to more efficiently broaden our pipeline of products, while continuing to capitalize on the rapidly growing pharmaceutical services market.”

Halo also has a manufacturing facility in Montreal. Its total 450-person workforce will join Cambrex’s 1,200 employees across the U.S. and Europe.

You May Have Missed...

Carl DiOrio

Carl DiOrio

Carl DiOrio is the managing editor for NJBIZ. You can reach him at cdiorio@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close